9905 related articles for article (PubMed ID: 1280153)
21. Curative cancer chemotherapy.
Frei E
Cancer Res; 1985 Dec; 45(12 Pt 1):6523-37. PubMed ID: 2998603
[TBL] [Abstract][Full Text] [Related]
22. The interferons.
Itri LM
Cancer; 1992 Aug; 70(4 Suppl):940-5. PubMed ID: 1379116
[TBL] [Abstract][Full Text] [Related]
23. Melanoma: therapeutic options with recombinant interferons.
Kirkwood JM; Ernstoff M
Semin Oncol; 1985 Dec; 12(4 Suppl 5):7-12. PubMed ID: 2417333
[TBL] [Abstract][Full Text] [Related]
24. Interferon therapy in cancer: from imaginon to interferon.
Goldstein D; Laszlo J
Cancer Res; 1986 Sep; 46(9):4315-29. PubMed ID: 2425950
[No Abstract] [Full Text] [Related]
25. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
Balmer CM
DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
[TBL] [Abstract][Full Text] [Related]
26. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
Oettgen HF
Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
[TBL] [Abstract][Full Text] [Related]
27. The role of interferons in the treatment of hematologic malignancies.
Gutterman JU
Semin Hematol; 1988 Jul; 25(3 Suppl 3):3-8. PubMed ID: 2459780
[TBL] [Abstract][Full Text] [Related]
28. The role of interferons in the treatment of malignant neoplasms.
Murren JR; Buzaid AC
Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
[TBL] [Abstract][Full Text] [Related]
29. [Clinical use of interferon].
Lauta VM
Clin Ter; 1996; 147(7-8):345-51. PubMed ID: 9118615
[TBL] [Abstract][Full Text] [Related]
30. [The interferon system. A review of biological principles and clinical uses].
Schneider FJ
Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
[TBL] [Abstract][Full Text] [Related]
31. Interferon in the treatment of cutaneous T-cell lymphoma.
Olsen EA; Bunn PA
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1089-107. PubMed ID: 8522486
[TBL] [Abstract][Full Text] [Related]
32. Update on the antitumor activity of alpha interferon.
Quesda JR
Oncology (Williston Park); 1988 Mar; 2(3):49-54. PubMed ID: 3079324
[TBL] [Abstract][Full Text] [Related]
33. Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas.
Skarin AT
Semin Oncol; 1986 Dec; 13(4 Suppl 5):10-25. PubMed ID: 2432666
[TBL] [Abstract][Full Text] [Related]
34. Interferon and other biologic agents for the treatment of Kaposi's sarcoma.
Krown SE
Hematol Oncol Clin North Am; 1991 Apr; 5(2):311-22. PubMed ID: 1708760
[TBL] [Abstract][Full Text] [Related]
35. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
36. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
Foon KA; Bunn PA
Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
[TBL] [Abstract][Full Text] [Related]
37. Biotherapy with interferon in hematologic malignancies.
Roth MS; Foon KA
Oncol Nurs Forum; 1987; 14(6 Suppl):16-22. PubMed ID: 2447569
[No Abstract] [Full Text] [Related]
38. Biologic therapy in patients receiving salvage treatment.
Bukowski RM
Semin Oncol; 1994 Aug; 21(4 Suppl 7):96-9. PubMed ID: 8091247
[TBL] [Abstract][Full Text] [Related]
39. Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma.
Borden EC
Semin Oncol; 1994 Dec; 21(6 Suppl 14):14-22. PubMed ID: 7992095
[TBL] [Abstract][Full Text] [Related]
40. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
